Citigroup Initiates Coverage On Bio-Rad Laboratories with Buy Rating, Announces $450 Price Target

Citigroup analyst Patrick Donnelly initiates coverage on Bio-Rad Laboratories (NYSE:BIO) with a Buy rating and a $450 price target.

Benzinga · 01/07/2020 12:07

Citigroup analyst Patrick Donnelly initiates coverage on Bio-Rad Laboratories (NYSE:BIO) with a Buy rating and a $450 price target.